Evaxion Posts $3.7M Q2 Loss, Cash Runway Into 2027; EVX-04 Filing Set for Year-End
EVAX sits 38% above its 52-week low of $2.52 on elevated volume (52× avg).
Summary
Evaxion reported Q2 2026 net loss of $3.7 million, slightly wider than Q1's $3.6 million but narrower than the $4.8 million loss a year ago, with the narrowing attributed to lower expenses. Cash and equivalents fell to $14.0 million from $18.4 million at end of Q1, but management reiterated runway into the second half of 2027. The company also confirmed it expects to submit the regulatory filing for its EVX-04 AML vaccine candidate before year-end and plans to expand into autoimmune disease programs in H2 2026. The update follows a series of positive pipeline announcements, including the new EVX-05 glioblastoma program with Duke and upcoming three-year EVX-01 data at ESMO in October. With a market cap around $26 million, the cash position and runway are critical; the reiterated guidance and near-term catalysts keep this on traders' radar.
At the time of this announcement, EVAX was trading at $3.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.3M. The 52-week trading range was $2.52 to $12.15. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.